Marrow donor platelet survival (day −15) in 15 canine recipients
| No. of recipients . | Platelet data . | Marrow rejection . | |
|---|---|---|---|
| Percentage recovery . | Days survival . | ||
| 5 | 12-75 (median 39) | 0.9-3.9 (median 1.5) | No |
| 7 | Refractory* | No | |
| 3 | Refractory* | Yes | |
| No. of recipients . | Platelet data . | Marrow rejection . | |
|---|---|---|---|
| Percentage recovery . | Days survival . | ||
| 5 | 12-75 (median 39) | 0.9-3.9 (median 1.5) | No |
| 7 | Refractory* | No | |
| 3 | Refractory* | Yes | |
In this study,11 dogs were given 6 weekly preceding blood product transfusions from their donors (beginning on day −50), procarbazine/ATS (beginning on day −8) before 920 cGy total body irradiation (day 0), and hematopoietic grafts from DLA-mismatched unrelated donors.
Less than 5% recovery.